Effect of ethnicity and chemotherapy (mFOLFOX6) on zolbetuximab pharmacokinetics in patients with claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ).

Keun-Wook Lee,Samuel J. Klempner,Jianning Yang,Amit Desai,Akihiro Yamada,Yoko Ueno,Tomasz Wojtkowski,Jung Wook Park,Janet Pavese,Fotios Loupakis,Yung-Jue Bang,Kohei Shitara

Effect of ethnicity and chemotherapy (mFOLFOX6) on zolbetuximab pharmacokinetics in patients with claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ).

2021

Keun-Wook Lee
Samuel J. Klempner
Jianning Yang
Amit Desai
Akihiro Yamada
Yoko Ueno
Tomasz Wojtkowski
Jung Wook Park
Janet Pavese
Fotios Loupakis
Yung-Jue Bang
Kohei Shitara

e16078Background: Zolbetuximab is a chimeric IgG1 monoclonal antibody that targets Claudin 18.2 (CLDN18.2), a tight junction protein that is normally confined to gastric mucosa but is retained in G...

Keywords:

Medicine
locally advanced
Tight junction
Gastric mucosa
Chemotherapy
Gastroesophageal Junction Adenocarcinoma
Claudin
Pharmacokinetics
Cancer research
Monoclonal antibody

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations